Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise

WESTMINSTER, Colo., Oct. 22, 2014 /PRNewswire/ -- Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents in minimally invasive direct-to-tumor interventional procedures, is pleased to announce that oncologist John R. Daniels, MD of the University of Southern California's Norris Comprehensive Cancer Center, and surgical oncologist Steven C. Katz, MD of the Roger Williams Medical Center have joined the Company's Scientific Advisory Board (SAB).   

"The role of the SAB is to provide guidance in clinical trial design and implementation.  With the additions of Dr. Daniels and Dr. Katz, Surefire is now poised to have the benefit of an interdisciplinary team that genuinely reflects the collaborative nature of Interventional Oncology," said SAB Chair Aravind Arepally, MD.

Prior to his current role as a clinician and Associate Professor of Medicine at USC's Division of Oncology, Dr. Daniels was a faculty member of the Stanford University School of Medicine.  He has authored more than 100 peer-reviewed articles and is also the founder of five medical technology companies including Target Therapeutics, which developed the Tracker steerable microcatheter.

"I hope to help design studies that may definitively establish to oncologists that there is now a way to treat lesions more effectively by increasing penetration into tumors," he says.

Dr. Katz, a surgical oncologist and Associate Professor of Surgery at the Roger Williams Medical Center in Rhode Island, focuses on the management of complex intrahepatic malignancies and T-cell therapies.  He served as the Principal Investigator for the Hepatic Immunotherapy for Metastases (HITM) clinical trial (NCT01373047) and is the recipient of numerous grants and awards, including an NIH grant for his immunotherapy laboratory.  He is a reviewer for several scientific and clinical journals and serves on the editorial boards of the Journal of Surgical Research and Cancer Gene Therapy.

"I have a strong interest in products that enable delivery of liver-directed therapies in a safer, more effective fashion," he says.

"We are extremely fortunate to benefit from both Dr. Daniels' and Dr. Katz's extensive clinical trial and oncology expertise as we continue to focus on enlarging the body of clinical evidence indicating that the Surefire Infusion System may advance effective, minimally invasive and cost-effective interventional treatments for cancers and beyond," said Surefire Medical President and CEO James E. Chomas. 

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the Interventional Radiology and Interventional Oncology markets.  Surefire's infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue.  The Surefire Infusion System and guiding catheters have received regulatory approval in the U.S., Europe, Canada, Australia, New Zealand and Taiwan.  www.surefiremedical.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/surefire-medicals-scientific-advisory-board-expands-broadens-clinical-trial-expertise-732070729.html

SOURCE Surefire Medical, Inc.

Related Links

http://www.surefiremedical.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED